We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Organon (OGN) Stock Falls Amid Market Uptick: What Investors Need to Know
Read MoreHide Full Article
In the latest trading session, Organon (OGN - Free Report) closed at $8.20, marking a -3.98% move from the previous day. This change lagged the S&P 500's daily gain of 0.54%. On the other hand, the Dow registered a gain of 1.05%, and the technology-centric Nasdaq increased by 0.56%.
Prior to today's trading, shares of the pharmaceutical company had gained 17.96% outpaced the Medical sector's loss of 1.89% and the S&P 500's gain of 0.74%.
Analysts and investors alike will be keeping a close eye on the performance of Organon in its upcoming earnings disclosure. The company's earnings report is set to go public on February 12, 2026. The company is predicted to post an EPS of $0.74, indicating a 17.78% decline compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $1.53 billion, showing a 3.84% drop compared to the year-ago quarter.
OGN's full-year Zacks Consensus Estimates are calling for earnings of $3.76 per share and revenue of $6.24 billion. These results would represent year-over-year changes of -8.52% and 0%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Organon. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.88% lower. Organon presently features a Zacks Rank of #5 (Strong Sell).
Looking at its valuation, Organon is holding a Forward P/E ratio of 2.23. This denotes a discount relative to the industry average Forward P/E of 15.89.
Investors should also note that OGN has a PEG ratio of 1.73 right now. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. OGN's industry had an average PEG ratio of 1.76 as of yesterday's close.
The Medical Services industry is part of the Medical sector. With its current Zacks Industry Rank of 181, this industry ranks in the bottom 27% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Organon (OGN) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Organon (OGN - Free Report) closed at $8.20, marking a -3.98% move from the previous day. This change lagged the S&P 500's daily gain of 0.54%. On the other hand, the Dow registered a gain of 1.05%, and the technology-centric Nasdaq increased by 0.56%.
Prior to today's trading, shares of the pharmaceutical company had gained 17.96% outpaced the Medical sector's loss of 1.89% and the S&P 500's gain of 0.74%.
Analysts and investors alike will be keeping a close eye on the performance of Organon in its upcoming earnings disclosure. The company's earnings report is set to go public on February 12, 2026. The company is predicted to post an EPS of $0.74, indicating a 17.78% decline compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $1.53 billion, showing a 3.84% drop compared to the year-ago quarter.
OGN's full-year Zacks Consensus Estimates are calling for earnings of $3.76 per share and revenue of $6.24 billion. These results would represent year-over-year changes of -8.52% and 0%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Organon. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2.88% lower. Organon presently features a Zacks Rank of #5 (Strong Sell).
Looking at its valuation, Organon is holding a Forward P/E ratio of 2.23. This denotes a discount relative to the industry average Forward P/E of 15.89.
Investors should also note that OGN has a PEG ratio of 1.73 right now. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. OGN's industry had an average PEG ratio of 1.76 as of yesterday's close.
The Medical Services industry is part of the Medical sector. With its current Zacks Industry Rank of 181, this industry ranks in the bottom 27% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.